NCT05941949

Brief Summary

This is a prospective, placebo controlled study, examining the effects of dietary supplement's effects on cognition and confirming safety.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 26, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

July 5, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 12, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

July 13, 2023

Status Verified

July 1, 2023

Enrollment Period

6 months

First QC Date

May 26, 2023

Last Update Submit

July 11, 2023

Conditions

Keywords

Dietary SupplementCognitionMemoryMental StressWellbeingAntioxidantAstaxanthinGrape Juice Extract

Outcome Measures

Primary Outcomes (4)

  • Change in working memory

    Determine change in working memory as measured by the Numeric Working Memory Test

    Baseline and Week 12

  • Change in Working memory by Corsi Block tasks

    Determine if working memory change by doing Corsi blocks task

    Baseline and Week 12

  • Change in verbal learning and memory

    Determine if verbal learning and memory change using total score on Rey Auditory Verbal Learning test trials 1 to 5

    Baseline and Week 12

  • Change in episodic memory

    Determine change in episodic memory as measured by Rey Auditory Verbal Learning Test delayed recall and computerized location learning task

    Baseline and Week 12

Secondary Outcomes (9)

  • Change in accuracy of attention

    Baseline and Week 12

  • Change in the Everyday Memory

    Baseline, Week 4, Week 8, Week 12

  • Change in the Perceived Stress score

    Baseline, Week 4, Week 8, Week 12

  • Change in the World Health Organization score

    Baseline, Week 4, Week 8, Week 12

  • Change in oxidative stress marker

    Baseline and Week 12

  • +4 more secondary outcomes

Other Outcomes (3)

  • Change in Ocular Surface Disease Index score

    Baseline, Week 4, Week 8, Week 12

  • Change in diastolic blood pressure measurement (safety measure)

    Baseline and Week 12

  • Change in systolic blood pressure measurement (safety measure)

    Baseline and Week 12

Study Arms (2)

Active

EXPERIMENTAL

Softgel containing: Astaxanthin, Grape Juice Extract, and All Natural Vitamin E

Dietary Supplement: Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E

Placebo

PLACEBO COMPARATOR

Softgel containing: Olive Oil and Sunflower Lecithin

Dietary Supplement: Placebo

Interventions

2 softgels per day

Also known as: Astaxanthin, Grape Juice Extract, All Natural Vitamin E
Active
PlaceboDIETARY_SUPPLEMENT

2 softgels per day

Also known as: Olive oil
Placebo

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Health Individuals
  • Residing in independent living accommodations
  • Subjective report of memory or attention problems by answering 'yes' to the following questions: Do you have problems with your memory, attention, or concentration?
  • Non-smoker
  • Body Mass Index (BMI) between 18-35 kg/m2
  • No plan to commence new treatments over the study period
  • Understand, willing and able to comply with all study procedures
  • Willing to provide a personally signed and dated informed consent form detailing all pertinent aspects of the study

You may not qualify if:

  • Diagnosis of dementia based on the revised National Institute on Aging-Alzheimer's Association (NIA/AA) criteria
  • A score below the 5th percentile for age, education, and gender on the Telephone Interview for Cognitive Status (TICS-M)
  • Suffering from recently diagnosed or unmanaged medical conditions including but not limited to diabetes, hyper/hypotension, cardiovascular disease, gallbladder disease, autoimmune disease, endocrine disease, or cancer/malignancy
  • Diagnosis of a psychiatric disease (other than mild-to moderate depression of anxiety) and/or neurological condition/disease (e.g. Parkinson's, Alzheimer's disease)
  • History of paralysis, stroke or seizures or head injury (with loss of consciousness)
  • Regular medication intake including but not limited to anticholinergics, acetylcholinesterase inhibiters, or steroid medications.
  • Taking vitamins or herbal supplements that are reasonably expected to influence study measures
  • In the last 6 month, commenced or changed the dose of nutritional and/or herbal supplements that may impact on treatment outcome
  • Alcohol intake greater than 14 standard drinks per week
  • Current or 12-month history of illicit drug abuse
  • Pregnant women, women who are Brest feeding, or women who intend to fall pregnant
  • Any significant surgeries over the last year
  • Planned major lifestyle change in the next 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Research Australia

Duncraig, Western Austrailia, 6023, Australia

RECRUITING

MeSH Terms

Conditions

Stress, Psychological

Interventions

astaxanthineOlive Oil

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

Dietary Fats, UnsaturatedDietary FatsFatsLipidsFats, UnsaturatedPlant OilsOilsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Adrian Lopresti, MD

    Clinical Research Australia

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Softgels with similar appearance
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized, Prospective, Double Blind, Placebo-Controlled design
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 26, 2023

First Posted

July 12, 2023

Study Start

July 5, 2023

Primary Completion

January 1, 2024

Study Completion

June 1, 2024

Last Updated

July 13, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will not share

No plan to share individual participant data. Will only report summary data i.e. means by responses to specific variables.

Locations